Test E + Anadrol Bulking (12 weeks)

testosterone: exogenous contribution in serum (ng/dL).

The body's own testosterone is excluded. This is the contribution from entered doses, not the total blood level.

Fixed reference profile: Ten adult men with hypogonadism already receiving IM testosterone enanthate; adult model reanalysis of the 2015 cohort. Testosterone enanthate 200 mg/mL in sesame oil (West-Ward), as studied in the IM reference cohort.; Intramuscular. Fixed reference weight: 90.35 kg.

Changing dose or schedule explores a scenario; it does not personalize the reference profile or establish a studied regimen.

Input dose basis: Nominal testosterone enanthate mg

Source exposure scope: The adult IM source cohort received a 200 mg study injection on existing treatment. Other schedules are simulations under fixed linear parameters, not additional observed regimens.

Adult IM testosterone enanthate: injected-drug model component

vogiatzi-2023-enanthate-im-component · version 1

• Published adult fixed-effect parameters; no individual random effects or pediatric allometric scaling.
• Zero initial exogenous amount and no endogenous testosterone contribution. Prior treatment is included only when its dose events are entered.
• Nominal testosterone enanthate dose enters the model directly; no additional ester-mass or bioavailability multiplier.

Model structure

One compartment with absorption

Apparent clearance (CL/F)

50.569 L/hour

Apparent central volume (Vc/F)

13755.8 L

Absorption rate (ka)

0.0831 /hour

Input mass conversion

1 mg modelled mass per mg entered

• This mathematical injected-drug component is not a measured fraction of an individual blood sample or a prediction of total testosterone.
• The small source cohort had prior treatment and variable endogenous testosterone. Clinical effects, endogenous recovery and fertility are not modeled.
• These IM parameters do not describe subcutaneous autoinjectors, other formulations or pediatric patients.
• Changing a simulated dose or interval does not establish treatment suitability, a testing date or an expected change in adverse effects.

• Vogiatzi et al. 2023 — adult IM population model

  Adult one-compartment model; pediatric simulations in the paper are not implemented.

• Vogiatzi et al. — supplementary Table 3 and Figures 7–8

  Full-precision IM fixed effects: Ka 0.0831/h, V 13755.8 L, CL 50.569 L/h. Figure 8 includes different initial endogenous levels, excluded from this component.

• Kaminetsky et al. 2015 — underlying clinical cohort

  The IM sesame-oil reference arm is separate from the subcutaneous autoinjector arms; observed total-testosterone endpoints are not isolated-dose peaks.

Tmax source 210 min÷60; 8 h is declared assumed terminal shape, not reverified primary parameter.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

8 hours

Absorption half-life assumed

1.031691 hours

Reference amount for the relative scale

1 mg

• The faster rate is inferred to match the 3.5 h source-scoped peak time; absorption half-life 1.0316907771179677 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Half-life 8 h retained as an explicit shape estimate; original abstract verifies peak/time but not terminal half or cohort count. Full article access was limited.
• Food state/formulation details and linear accumulation are not fully established.
• No extra 0.95 F multiplier; observed oral endpoint already contains absorption.

• Cardoso 2002 oxymetholone human plasma assay/PK

  50 mg oral healthy-volunteer dose gave 18.8 ng/mL peak at 210 min; extraction recovery is not oral F.

anadrol-relative-timing-2026-10 · version 1